<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138033">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124681</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13060248</org_study_id>
    <nct_id>NCT02124681</nct_id>
  </id_info>
  <brief_title>Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer</brief_title>
  <acronym>REHNIS</acronym>
  <official_title>Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current options to treat insulin resistance in diabetes are fairly limited. For this reason,
      novel treatments would represent a major progress. The generic drug hydroxychloroquine (HCQ)
      has poorly understood effects on blood sugar metabolism. In this study, the investigators
      will examine the mechanisms by which this drug affects glucose metabolism and which cells
      are affected. Findings emanating from this project will help establish whether HCQ may be a
      viable treatment for disorders of glucose metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Insulin sensitivity in muscle and liver</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>biomarkers of inflammation</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine Dose: 400mg PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400 mg/d</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-69 years-old;

          -  BMI 28-40;

          -  Presence of at least one of the following markers of insulin resistance: a) fasting
             hyperinsulinemia (&gt;7 uU/ml by ultrasensitive insulin assay); impaired fasting glucose
             (100-125 mg/dl); prior history of impaired glucose tolerance provided by the
             participant; history of previous gestational diabetes; history of PCOS; waist
             circumference &gt;40&quot; (men) or &gt;35&quot; (women) (cut-offs from ATP-III criteria for
             metabolic syndrome).

        Exclusion Criteria:

          -  Pregnancy, or unable/unwilling to avoid pregnancy during the study;

          -  Unstable cardiopulmonary disease, hepatitis, liver dysfunction, renal insufficiency,
             or any other medical condition affecting glucose metabolism or safety during the
             study;

          -  Diabetes;

          -  Medications that affect glucose metabolism: (e.g. systemic glucocorticoids,
             antipsychotics);

          -  History of hypersensitivity to local lidocaine, similar anesthetics, or HCQ;

          -  History of G6PDH deficiency;

          -  History of retinopathy;

          -  Weight instability (&gt;3Kg of weight change in the past three months);

          -  Bariatric surgery in the last two years, intention to lose weight or engage in
             exercise regimen during study;

          -  Alcohol intake &gt;1 drink/day (averaged);

          -  Hemoglobin &lt;10g%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederico Toledo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikki L Helbling, RN</last_name>
    <phone>412-692-2285</phone>
    <email>nlr8@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelli Lange</last_name>
    <phone>412-692-2848</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Montefiore Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Helbling, RN</last_name>
      <phone>412-692-2285</phone>
      <email>nlr8@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Frederico Toledo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Frederico Toledo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
